Postoperative pathology confirmed poorly differentiated endometrioid adenocarcinoma (International Federation of Gynecology and Obstetrics IIIC2 stage), with immunohistochemistry showing estrogen receptor/progesterone receptor (PR) negativity, p53 mutation pattern, and nonspecific molecular profile. This evidence concerns the gene PGR and endometrioid adenocarcinoma.